This is a mobile optimized page that loads fast, if you want to load the real page, click this text.

TLX - Telix Pharmaceuticals

Jump to new
Miner said:
Post fda announcement price dropped.
Market was expecting this ?
Click to expand...

but wait, there's more (or less)

Telix Pharmaceuticals is immediately cancelling the share purchase plan it announced in January due to changing market conditions. The cancellation does not affect the recently completed share placement to institutional investors which raised $175 million at $7.70 per share.

“The decision to cancel the share purchase plan was made by the board after considering current market conditions, which have changed significantly in recent weeks,” the company said.
Click to expand...

.... yep, those dang "market conditions" ........ was below $5 this morning.

(DNH)
 
Poor inept insto to see the market while spending on investors money.
 
Telix Pharmaceuticals has recorded $22.5 million in global sales for its Illucix cancer imaging and diagnosis product.

Net cash outflows for the June quarter were $25.8 million, and as at June 30 it had cash on hand of $122.6 million.
....
back in good books; up 16% to $6.50 (as low as $3,55 in May this year)
 
Telix Pharmaceuticals has dropped 15 per cent, now $4.58, after the company withdrew its application for marketing authorisation for Illuccix in Europe in what it describes as an "unexpected " and "extremely disappointing" result.

In a statement, Telix advised that in the late stages of review, the Danish Medicines Agency requested additional Chemistry, Manufacturing and Control data.
 
  • Revenues have surged 41 per cent to $78.2 million in the third quarter of 2022, as US sales jumped.
  • Net cash flow of $1.6 million, the first positive quarter from operations.
  • US Illuccix sales jumped 43 per cent in the quarter, compared with the previous period, to $76.8 million.
  • Dose demand in the US continued to expand month on month.
...And back above $7
 
One I own that's going well even in this market. great future and anything Dona likes
 
My pick.
On holiday so just going for a favourite of mine. Well run and regularly subject to good news.
 
Telix Pharmaceuticals submitted a license application to the US Food and Drug Administration for a radiopharmaceutical imaging agent for kidney cancer.

If approved by the FDA, TLX250CDx will become the first such technology to be commercially available to patients in the US.

There's a request for priority review, which, if granted, would support an expedited review time.

and so the news flow keeps coming.
.
$9.56
 
TLX is my fourth tip for CY 24 (@Sean K and @debtfree - please confirm if my four tips for CY 2024 met the criteria or scratched off for technicalities. I would amend the error as there is still time to meet the deadline)
TLX is relatively on a high price side and compared to minnows, it may not rise high.
But I have sentimental value attached to it. This was one of the stocks which gave me a great upside over last few years and now do not hold.
Please refer to recent announcements and they are really encouraging. Specially for prostate enlargement and kidney patients, their discovery will be a great benefits for company to make money (see CSL ) and patients to get the benefits. It will not be long that the extension of kidney cancer imaging will be extended to pancreatic cancer imaging as well (mark my word in 2025).



 
My yearly pick. Really umming and ahhing on this one.
Imaging tech and needs a partner long term.
Short term factors keeping price down but long term should do very well. Pretty confident of $12 (20% rise) but really want 50% rise.($15)
Might regret this if BFG does better. Almost changed my mind.
 
good picks, guys.
.
Telix is considering an initial public offering of American Depositary Shares representing its ordinary shares in the United States and listing on the Nasdaq Global Market. Telix’s ordinary shares will remain listed on the Australian Securities Exchange.

The number of ADSs that may be offered, the number of underlying ordinary shares that may be issued, the price for such instruments and the timing of the offering have not yet been finalized. A registration statement relating to Telix’s ADSs to be sold in the proposed offering is expected to be filed with the U.S. Securities and Exchange Commission, any securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective which is subject to a U.S. SEC review process, market conditions, investor demand and customary corporate approvals. No final decision has been made in respect of the offering or Nasdaq listing and there can be no assurance as to the occurrence, timing, pricing and/or completion of such an offering or listing.
 
Knobby22 said:
Telix to list in the USA
probably will improve price as Australians dont understand pharma generally.
Click to expand...
looking more and more a stateside company

And an acquisition. ... shares upfront, and 3x in cash if conditions met

TLX has entered into an agreement to acquire QSAM Biosciences, Inc. (OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP.

QSAM is a United States based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer. 153Sm-DOTMP is a novel kit-based bone-seeking targeted radiopharmaceutical candidate that uses a “next generation” chelating agent to deliver a proprietary formulation of Samarium-153 radioisotope.

With two major potential applications – pain management of bone metastases and osteosarcoma therapy, including in paediatric patients – 153Sm-DOTMP is highly aligned with Telix’s existing therapeutic focus areas in urologic oncology (prostate cancer), neuro-oncology (glioma), and musculoskeletal oncology (sarcoma).


.
and getting back to earlier highs
 
Last edited:
Making a profit now.

2023 highlights

• Total Group revenue of $502.5M, an increase of 214% from $160.1M in 2022 primarily driven by continued strong

growth in sales of Illuccix® in the second year since commercial launch (April 2022)

• Delivered positive adjusted earnings before interest, tax, depreciation, and amortisation (adjusted EBITDA) of $58.4M

an increase of $126.2M, compared to a loss of $67.8M in 2022

• Inaugural full year profit of $5.2M after tax. A substantial improvement on the net loss after tax of $104.1M in 2022

• Investment in research and development (R&D) and selling, general and administration (SG&A) reflects progress

across the late-stage pipeline and scale-up of the commercial organisation

• Overall operating costs as a percentage of revenue have reduced to 52% from 105% in 2022

• Gross margin has improved to 63% (vs. 59% in 2022) reflecting distribution and manufacturing costs optimisation

• Positive operating cash inflow in line with commercial sales growth, demonstrated through customer receipts of

$463.7M (vs. $124.1M in 2022), and

• Closing cash balance was $123.2M as at 31 December 2023.
 
You must log in or register to reply here.

Similar threads

CU6 - Clarity Pharmaceuticals
2
Replies
33
Views
7K
Dona Ferentes
O
INEX Pharmaceuticals: Great licensing agreement with Hana Biosciences
Replies
3
Views
5K
ollinbg
O
Menu
Log in
Register
Cookies are required to use this site. You must accept them to continue using the site. Learn more...